[1] 赵正斌,范文海.老年慢性乙型肝炎患者基因多态性与其耐药变异的相关性[J].中国老年学杂志,2017,37(2):417-419. [2] KUO M T,TSENG P L,CHOU Y P, et al. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy[J]. J Gastroenterol Hepatol, 2018,33(10):1766-1772. [3] LIAW Y F,KAO J H,PIRATVISUTH T, et al.Erratum to:Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].Hepatol Int, 2012,6(4):809-810. [4] HOU J, WANG G, WANG F, et al.Guideline of prevention and treatment for chronic hepatitis B (2015 Update)[J].J Clin Transl Hepatol, 2017,5(4):297-318. [5] KIM B C,JUNG S W,KIM E H,et al. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir[J]. J Gastroenterol Hepatol, 2015,30(10):1514-1521. [6] 谭俊,周密,胡皓钧,等.替诺福韦酯片对乙肝病毒感染经治患者补救治疗的疗效研究[J].中华医院感染学杂志,2017,27(21):4837-4841. [7] 邱英锋,王淑英.长期应用恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎患者临床疗效及安全性分析[J].实用肝脏病杂志,2018,21(2):196-199. [8] 孔洪彬,宁振海,赵斗贵,等.恩替卡韦联合阿德福韦酯治疗拉米夫定耐药的慢性乙型肝炎患者疗效观察[J].肝脏,2018,23(1):88-90. [9] 李连海,齐敏.不同核苷类似物治疗乙型肝炎肝硬化失代偿期的疗效及对相关炎性细胞因子水平的影响[J].广西医科大学学报,2016,33(5):849-851. [10] 李秀梅,梁树人,李顺天,等.乙型肝炎患者外周血T细胞亚群的分析及意义[J].山东医药,2012,52(20):63-65. [11] 刘宁,徐杰,刘金花, 等.慢性乙型肝炎、乙肝肝硬化、乙肝肝癌患者Th1/Th2型细胞因子水平变化研究[J].胃肠病学和肝病学杂志,2014,23(2):158-161. [12] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版)[J].实用肝脏病杂志,2016,19(03):389-400. [13] VAN HEES S, BOURGEOIS S,VAN VLIERBERGHE H, et al. Stopping nucleos(t)ide analogue treatment in Caucasianhepatitis Bpatients after HBeAg seroconversion is associated with high relapse rates and fataloutcomes[J]. Aliment Pharmacol Ther, 2018,47(8):1170-1180. [14] YANG H C, SHIH Y F, LIU C J.Viralfactorsaffecting theclinicaloutcomesofchronic hepatitis B[J].J Infect Dis, 2017,216(suppl_8):S757-S764. [15] 王肖,王鹤,刘元元.替诺福韦酯与拉米夫定治疗老年慢性乙型肝炎的疗效比较[J].中国老年学杂志,2017,37(12):2978-2979. [16] KESKIN O,ORMECI A C,BARAN B,et al. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B[J]. Antivir Ther(Lond), 2014,19(6):543-550. [17] POL S,LAMPERTICO P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings:from clinical trials to clinical practice[J]. J Viral Hepat, 2012, 19(6):377-386. [18] 李忠斌, 邵清, 李梵, 等. 替诺福韦酯单独与联合恩替卡韦挽救治疗恩替卡韦治疗拉米夫定经治慢性乙型肝炎失败患者疗效比较[J]. 肝脏,2016,21(3):165-167,208. [19] 汪梦.替诺福韦酯与拉米夫定治疗慢性乙肝疗效与安全性比较[J].当代医学,2018,24(7):107-109. [20] 丁荣蓉, 施光峰, 张占卿, 等. 替诺福韦酯和恩替卡韦对慢性乙型肝炎初治患者疗效的荟萃分析[J]. 肝脏,2017,22(5):400-403. [21] YANG N,FENG J,ZHOU T, et al. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients[J]. J Med Virol, 2018,90(7):1240-1245. [22] WONG D,LITTLEJOHN M,EDWARDS R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B[J]. Liver Int, 2018,38(10):1760-1769. [23] 胥松,顾行军,杨国旗,等.慢性乙肝与肝硬化患者血清IL-2、IL-6、IL-10、ChE和HA变化临床价值[J].国际检验医学杂志,2014,35(15):1986-1988. [24] 石庆凤, 曾维群, 陈敏, 等. IL-10、TNF-α对慢性乙型肝炎患者树突状细胞的影响[J].免疫学杂志, 2009, 25(3):311-313,317. [25] 高沿航.恩替卡韦与替诺福韦治疗的慢性乙型肝炎患者发生肝细胞癌的风险:一项韩国全国性队列研究[J].临床肝胆病杂志,2018,34(12):2664. |